Pfizer Competitive Grant RFP: Brentuximab Vedotin-Based Novel Combination Interventional Studies in AITL and PTCL-NOS

About this program

Pfizer's Competitive Grant Program seeks US‑based investigator‑sponsored interventional studies to generate clinical evidence for brentuximab vedotin–based novel combination therapies in angioimmunoblastic T‑cell lymphoma (AITL) and peripheral T‑cell lymphoma‑not otherwise specified (PTCL‑NOS), irrespective of CD30 expression. Individual projects requesting up to $500,000 (inclusive of direct costs and overhead capped at 28%) will be considered for up to 3 years; submission deadline August 26, 2026 with anticipated award notification September 16, 2026. Eligible applicants are organizations (not individuals or independent physician practice groups) based in the United States, with a Principal Investigator holding an MD, PhD, or other qualifying clinical/research degree (or advanced nursing, pharmacy, physiotherapy, or social work degree) who is employed or contracted by the requesting organization; multi‑institution collaborations are permitted if all parties have defined roles. Applications must propose independent ISR protocols (not already initiated), confirm the institution can receive Pfizer funding, include required regulatory/IRB approvals upon award, and disclose any use of AI in application preparation.